A clinical measure of DNA methylation predicts outcome in de novo acute myeloid leukemia.

ABSTRACT:

Background

Variable response to chemotherapy in acute myeloid leukemia (AML) represents a major treatment challenge. Clinical and genetic features incompletely predict outcome. The value of clinical epigenetic assays for risk classification has not been extensively explored. We assess the prognostic implications of a clinical assay for multilocus DNA methylation on adult patients with de novo AML.

Methods

We performed multilocus DNA methylation assessment using xMELP on samples and calculated a methylation statistic (M-score) for 166 patients from UPENN with de novo AML who received induction chemotherapy. The association of M-score with complete remission (CR) and overall survival (OS) was evaluated. The optimal M-score cut-point for identifying groups with differing surviv

SUBMITTER: Luskin MR 

PROVIDER: S-EPMC4951094 | biostudies-literature | 2016 Jun

REPOSITORIES: biostudies-literature